DR-399 Molecular signature scores related to intratumor heterogeneity and stemness to improve prognostic accuracy and facilitate the development of more personalized treatment strategies for breast cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-399 Molecular signature scores related to intratumor heterogeneity and stemness to improve prognostic accuracy and facilitate the development of more personalized treatment strategies for breast cancer
We aim to characterize Immuno-evasive stem cells genetic signatures to better understand their behavior within breast cancer. These cells play …
DR-407 Liver metastases exhibit a distinct myeloid-dominated tumor microenvironment characterized by dense infiltration of VEGFR1+ VEGF-A-secreting macrophages
Liver metastases (LM) are a major obstacle for patients with advanced non-squamous non-small cell lung cancer. We stratified 1,713 treatment-naïve …
DR-402 Predicting response to immune-checkpoint inhibitors in metastatic cancer using Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score
Immune checkpoint inhibitors (ICIs) have significantly improved clinical outcomes of patients with metastatic cancers. In clinical practice, three biomarkers are …
DR-385 Development of computational multi-omics strategies for targeting therapeutically the tumour metastasis and tumour microenvironment heterogeneity
Identifying the most appropiate therapies based on cancer genome data is a major challenge in personalized cancer medicine. Physicians and researchers face …
DR-375 AI-driven classification of metastatic tumors with MSI/MSS phenotypes: an integrative computational and clinical perspective
We aim to provide insights into cancer progression and therapy responsiveness by combining diverse molecular sequence data using an AI-driven multimodal classifier. …
DR-395 Predicting the landscape and dynamic of cancer drivers from cancer initiation to metastasis
Cancer initiation and progression are a result of acquiring alterations in genes that confer a selective advantage to the cell …
DR-382 An international multicenter retrospective study on the efficacy of anti-PD-(L)1 monotherapy in microsatellite unstable castrate-resistant prostate cancer
Metastatic castrate-resistant prostate cancer (mCRPC) is generally insensitive to immune checkpoint inhibitor therapy (ICIs), partly due to its relatively low …
DR-383 Drug resistance in cancer from in vitro genetic screens
Drug resistance is a major limitation to the long-term efficacy of cancer drugs. The use of cancer genome sequencing has …
DR-392 Targeting Genetic Alterations Associated with Metastatic Clear Cell Renal Cell Carcinoma
We aim to perform an integrated analysis of the genetic alterations associated with metastatic clear cell renal cell carcinoma (ccRCC) …
DR-389 Multi-omics pan-cancer profiling
The changes to the DNA (mutations) found in a tumour are expected to be largely unique to each tumour as …
DR-393 Distinctive size classes of loss of heterozygosity and homozygous deletion and its association with cancer progression and DNA repair pathways
Previous work from our institute has been published on analysis of WGS data that were made accessible by the Hartwig …
DR-377 Characterising the mutational landscape and recurrent somatic driver events to uncover therapeutic susceptibilities in pancreatic cancer
Pancreatic Adenocarcinoma (PAAD) has the highest rate of morbidly for all solid tumours, and with pancreatectomy possible in <20% patients, …
De complete DNA-test is een belangrijke stap op weg naar behandeling van vormen van kanker die nu nog niet behandeld kunnen worden met doelgerichte medicijnen.